Patents by Inventor Tokiko Asami
Tokiko Asami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10793575Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.Type: GrantFiled: November 24, 2017Date of Patent: October 6, 2020Assignee: CARNA BIOSCIENCES, INC.Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
-
Publication number: 20200055848Abstract: Herein disclosed are compounds, compositions, kits, and methods of treating cancers using 7-azaindolyl furanone/thiophene derivatives. These derivatives inhibit serine-threonine kinase Cdc7, a recognized anticancer target affecting DNA replication. Further, the compounds disclosed herein possess potent inhibitory activity in the presence of adenosine triphosphate (ATP), demonstrate significant kinase selectivity, and offer advantages over known Cdc7 inhibitors with prolonged half-life and inhibitory effects.Type: ApplicationFiled: November 2, 2017Publication date: February 20, 2020Inventors: Takayuki IRIE, Ayako SAWA, Masaaki SAWA, Tokiko ASAMI, Yoko FUNAKOSHI, Chika TANIYAMA
-
Publication number: 20190359616Abstract: The present invention provides with an oxoisoquinoline derivative represented by the formula (I) (in the formula, Q and R1 are as defined in the description) or a pharmaceutically acceptable salt thereof, which is useful as a Bruton's kinase inhibitor for treating cancer, B-cell lymphoma, chronic lymphocytic leukemia and the like.Type: ApplicationFiled: November 24, 2017Publication date: November 28, 2019Applicant: CARNA BIOSCIENCES, INC.Inventors: Wataru KAWAHATA, Takao KIYOI, Takayuki IRIE, Tokiko ASAMI, Masaaki SAWA, Shigeki KASHIMOTO
-
Patent number: 9974795Abstract: Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is —COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom.Type: GrantFiled: January 26, 2015Date of Patent: May 22, 2018Assignee: CARNA BIOSCIENCES, INC.Inventors: Yoko Funakoshi, Chika Tanaka, Tokiko Asami, Masaaki Sawa
-
Patent number: 9656995Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 15, 2014Date of Patent: May 23, 2017Assignee: CARNA BIOSCIENCES, INC.Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
-
Publication number: 20170065609Abstract: Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is —COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom.Type: ApplicationFiled: January 26, 2015Publication date: March 9, 2017Inventors: Yoko FUNAKOSHI, Chika TANAKA, Tokiko ASAMI, Masaaki SAWA
-
Publication number: 20160221991Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, either of Z1 and Z2 represents carbon atom and the other is nitrogen atom, or both of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) and (b) described below: wherein R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Inventors: Takahiro MIYAKE, Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA
-
Publication number: 20160207906Abstract: To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I): A 2,6-diaminopyrimidine derivative is represented by the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, Z1 and Z2 represent carbon atoms, or either 1 or 2 of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) or (b) described below: R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.Type: ApplicationFiled: September 1, 2014Publication date: July 21, 2016Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Takayuki IRIE
-
Publication number: 20160168122Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 15, 2014Publication date: June 16, 2016Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Yuko ASAMITSU, Takayuki IRIE, Takahiro MIYAKE, Takao KIYOI
-
Publication number: 20150011751Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturateType: ApplicationFiled: March 7, 2013Publication date: January 8, 2015Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
-
Patent number: 8742113Abstract: To provide a novel furanone derivative, and a medicine including the same.Type: GrantFiled: March 30, 2012Date of Patent: June 3, 2014Assignees: SBI Biotech Co., Ltd., Carna Biosciences, Inc.Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka
-
Publication number: 20140018533Abstract: To provide a novel furanone derivative, and a medicine including the same.Type: ApplicationFiled: March 30, 2012Publication date: January 16, 2014Applicants: CARNA BIOSCIENCES, INC., SBI BIOTECH CO., LTD.Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka
-
Patent number: RE46815Abstract: To provide a novel furanone derivative, and a medicine including the same.Type: GrantFiled: June 2, 2016Date of Patent: May 1, 2018Assignee: Carna Biosciences, Inc.Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka
-
Patent number: RE48140Abstract: To provide a novel furanone derivative, and a medicine including the same.Type: GrantFiled: April 30, 2018Date of Patent: August 4, 2020Assignee: CARNA BIOSCIENCES, INC.Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka